Lead Product(s) : RN1871
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rona gets NMPA IND Approval for AGT-Targeting siRNA Drug RN1871
Details : RN1871, a small interfering RNA (siRNA) drug targeting angiotensinogen. It is currently being evaluated for the treatment of hypertension.
Product Name : RN1871
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
April 21, 2025
Lead Product(s) : RN1871
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : T20G
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Triastek's 3D-Printed Gastric Retention Product T20G Receives FDA IND Clearance
Details : T20G is a non-vitamin K antagonist oral anticoagulant (NOAC) product, which is currently being evaluated for the treatment of atrial fibrillation.
Product Name : T20G
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 20, 2025
Lead Product(s) : T20G
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Benzenesulfonic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CureGene Receives Clinical Trial Approval in China for CG-0255 Antiplatelet Therapy
Details : CG-0255 is an advanced P2Y12 receptor antagonist developed as a next-generation antiplatelet therapy, for the treatment of coronary artery disease.
Product Name : CG-0255
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 12, 2024
Lead Product(s) : Benzenesulfonic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HiCM-188
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HELP Clears IND for iPSC-Derived HiCM-188 Therapy for End-Stage Heart Failure
Details : HiCM-188 is the first investigational iPSC-derived cell therapy to undergo clinical evaluation for the treatment of end-stage heart failure.
Product Name : HiCM-188
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 22, 2024
Lead Product(s) : HiCM-188
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : T22
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Triastek’s 3D Printed Product T22 Receives FDA Clearance for IND Application
Details : T22 is a world's first 3D printed gastric retention product. It is being evaluated in preclinical studies for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Product Name : T22
Product Type : Peptide
Upfront Cash : Inapplicable
January 31, 2024
Lead Product(s) : T22
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HiCM-188
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HiCM-188, a human (allogeneic) iPS cell-derived cardiomyocyte therapy in patients with worsening ischemic heart failure. HiCM-188 electrically couple with the patient's myocardium to generate contractile force (remuscularization).
Product Name : HiCM-188
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 30, 2023
Lead Product(s) : HiCM-188
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Ming Bioventures
Deal Size : $25.0 million
Deal Type : Series C Financing
Help Therapeutics Completes Series C Financing of 25 Million Dollars
Details : The financing will help the company conduct and complete clinical trials of its fully independent intellectual property development pipeline, iPSC heart cell injection, and will initiate clinical studies of immune cell therapy based on iPSC technology wi...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 27, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Ming Bioventures
Deal Size : $25.0 million
Deal Type : Series C Financing